Literature DB >> 11397840

Growth hormone (GH) secretion in patients with an inactivating defect of the GH-releasing hormone (GHRH) receptor is pulsatile: evidence for a role for non-GHRH inputs into the generation of GH pulses.

F Roelfsema1, N R Biermasz, R G Veldman, J D Veldhuis, M Frölich, W H Stokvis-Brantsma, J M Wit.   

Abstract

GH secretion is regulated by the interaction of GHRH and somatostatin and is released in 10-20 pulses in each 24-h cycle. The exact roles in pulse generation played by somatostatin, GHRH, and the recently isolated GH-releasing peptide, Ghrelin, are not fully elucidated. To investigate the GHRH-mediated GH secretion in human, we investigated pulsatile, entropic, and 24-h rhythmic GH secretion in two young adults (male, 24 yr; female, 23 yr) from a Moroccan family with a novel inactivating defect of the GHRH receptor gene. Data were compared with values in age- and gender-matched controls. Plasma GH concentration were measured by a sensitive immunofluorometric assay, with a detection limit of 0.01 mU/L. All plasma GH concentrations in the female patient were measurable; in the male patient 30 of 145 samples were at or below the detection limit. GH secretion was pulsatile, with 21 and 23 secretory episodes/24 h in the male and female patients, respectively. The fraction of basal to total GH secretion was raised in both patients by 0.18 and 0.15, respectively. The total 24-h GH production rate was greatly diminished; in the male patient it was 6.9 mU/L (normal values for his age, 26--63 mU/L), and in the female patient it was 4.2 mU/L (normal values for her age, 96--390 mU/L). The nyctohemeral plasma GH rhythm was preserved (P < 0.001), with normal acrophases (0430 and 0218 h in the male and female, respectively). Approximate entropy was greatly elevated in both subjects (0.82 in the male and 1.17 in the female; upper normal values for age and gender, 0.24 and 0.59, respectively). Intravenous injection of 50 microg GHRH failed to increase the plasma GH concentration in both patients, but 100 microg GH-releasing peptide-2 elicited a definite increase (male patient, 0.13 to 1.74 mU/L; female patient, 0.29 to 0.87 mU/L). Both patients had a partial empty sella on magnetic resonance imaging scanning. In summary, the present studies in two patients with a profound loss of function mutation of the GHRH receptor favor the view that in the human the timing of GH pulses is primarily supervised by intermittent somatostatin withdrawal, and the amplitude of GH pulses is driven by GHRH. In addition, we infer that effectual GHRH input controls the GH cell mass and the orderliness of the secretory process.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11397840     DOI: 10.1210/jcem.86.6.7536

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

Review 1.  Growth hormone and IGF-1.

Authors:  Roberto Salvatori
Journal:  Rev Endocr Metab Disord       Date:  2004-03       Impact factor: 6.514

2.  GH response to hypoglycemia and clonidine in the GH-releasing hormone resistance syndrome.

Authors:  R Salvatori; M G Serpa; G Parmigiani; A V O Britto; J L M Oliveira; C R P Oliveira; C M Prado; C T Farias; J C Almeida; T A R Vicente; M H Aguiar-Oliveira
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

3.  Determinants of dual secretagogue drive of burst-like growth hormone secretion in premenopausal women studied under a selective estradiol clamp.

Authors:  Dana Erickson; Daniel M Keenan; Leon Farhy; Kristi Mielke; Cyril Y Bowers; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

4.  Regulation of basal, pulsatile, and entropic (patterned) modes of GH secretion in a putatively low-somatostatin milieu in women.

Authors:  Johannes D Veldhuis; Susan A Hudson; Joy N Bailey; Dana Erickson
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-06-02       Impact factor: 4.310

5.  Short-term estradiol supplementation potentiates low-dose ghrelin action in the presence of GHRH or somatostatin in older women.

Authors:  Catalina Norman; Nanette Rollene; Suanne M Weist; Jean R Wigham; Dana Erickson; John M Miles; Cyril Y Bowers; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

6.  Implantable multireservoir device with stimulus-responsive membrane for on-demand and pulsatile delivery of growth hormone.

Authors:  Seung Ho Lee; Huiyan Piao; Yong Chan Cho; Se-Na Kim; Goeun Choi; Cho Rim Kim; Han Bi Ji; Chun Gwon Park; Cheol Lee; Chong In Shin; Won-Gun Koh; Young Bin Choy; Jin-Ho Choy
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-23       Impact factor: 11.205

7.  Estradiol regulates GH-releasing peptide's interactions with GH-releasing hormone and somatostatin in postmenopausal women.

Authors:  Catalina Norman; Nanette L Rollene; Dana Erickson; John M Miles; Cyril Y Bowers; Johannes D Veldhuis
Journal:  Eur J Endocrinol       Date:  2013-11-29       Impact factor: 6.664

8.  Integrating GHS into the Ghrelin System.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Int J Pept       Date:  2010-03-18

9.  Unusual phenotypic features in a patient with a novel splice mutation in the GHRHR gene.

Authors:  Latifa Hilal; Yassir Hajaji; Marie-Pierre Vie-Luton; Zeina Ajaltouni; Bouchra Benazzouz; Maha Chana; Adelmajid Chraïbi; Abdelkrim Kadiri; Serge Amselem; Marie-Laure Sobrier
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

10.  Novel relationships of age, visceral adiposity, insulin-like growth factor (IGF)-I and IGF binding protein concentrations to growth hormone (GH) releasing-hormone and GH releasing-peptide efficacies in men during experimental hypogonadal clamp.

Authors:  Johannes D Veldhuis; Daniel M Keenan; Joy N Bailey; Adebordurin M Adeniji; John M Miles; Cyril Y Bowers
Journal:  J Clin Endocrinol Metab       Date:  2009-04-07       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.